Genome-Wide Association Studies in Drug-Induced Liver Injury: Step Change in Understanding the Pathogenesis

Guruprasad P. Aithal; Jane I. Grove

doi:10.1055/s-0035-1567829

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2015; 35(04): 421-431
DOI: 10.1055/s-0035-1567829

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Genome-Wide Association Studies in Drug-Induced Liver Injury: Step Change in Understanding the Pathogenesis

Guruprasad P. Aithal

¹National Institute for Health Research (NIHR), Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, United Kingdom

,

Jane I. Grove

¹National Institute for Health Research (NIHR), Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, United Kingdom

› Author Affiliations

Abstract

Hepatotoxicity constrains drug development and accounts for a substantial burden on health services. Genome-wide association studies (GWASs) have investigated potential genetic factors that explain interindividual variations in response to medications leading to drug-induced liver injury (DILI). Although the proportion of GWASs investigating DILI is very small, those that have focused on this area have identified risk alleles with substantially higher risk ratios for susceptibility to DILI when compared with GWASs involving the majority of other complex diseases. Moreover, a relatively small number of human leukocyte antigen alleles are associated with DILI secondary to a range of medications. Because the encoded major histocompatibility complex proteins mediate antigen presentation to T cells, this provides evidence for a crucial central role for the adaptive immune system in DILI. Findings of GWASs should be considered during preclinical development of certain drugs. Genotyping may also have clinical applications, although it is currently limited to particular scenarios in relation to specific drugs.

Keywords

genome-wide association studies - drug-induced liver injury - hepatotoxicity - human leukocyte antigen - pharmacogenetics

Full Text

References

References
1 Aithal GP, Watkins PB, Andrade RJ , et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89 (6) 806-815
2 Stevens JL, Baker TK. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 2009; 14 (3–4) 162-167
3 Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144 (7) 1419-1425 , 1425.e1–1425.e3, quiz e19–e20
4 Donaghy L, Barry FJ, Hunter JG , et al. Clinical and laboratory features and natural history of seronegative hepatitis in a nontransplant centre. Eur J Gastroenterol Hepatol 2013; 25 (10) 1159-1164
5 Reuben A, Koch DG, Lee WM ; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52 (6) 2065-2076
6 Ulrich RG. Idiosyncratic toxicity: a convergence of risk factors. Annu Rev Med 2007; 58: 17-34
7 Björnsson E, Aithal G. Immune-mediated drug-induced liver injury. In: Gershwin ME, Vierling JM, Manns MP, eds. Liver Immunology. Heidelberg, Germany: Springer International Publishing; 2014: 401-412
8 Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007; 132 (1) 272-281
9 Aithal GP. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol 2011; 7 (3) 139-150
10 Aithal GP, Day CP. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 2007; 11 (3) 563-575 , vi–vii vi–vii
11 Hautekeete ML, Horsmans Y, Van Waeyenberge C , et al. HLA association of amoxicillin-clavulanate—induced hepatitis. Gastroenterology 1999; 117 (5) 1181-1186
12 O'Donohue J, Oien KA, Donaldson P , et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47 (5) 717-720
13 Donaldson PT, Daly AK, Henderson J , et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 2010; 53 (6) 1049-1053
14 Cai Y, Yi J, Zhou C, Shen X. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS ONE 2012; 7 (10) e47769
15 Urban TJ, Daly AK, Aithal GP. Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis 2014; 34 (2) 123-133
16 Holmes MV, Casas JP, Hingorani AD. Putting genomics into practice. BMJ 2011; 343: d4953
17 Hindorff LAMJ, Morales J, Junkins HA, Hall PN, Klemm AK, Manolio TA. A catalog of published genome-wide association studies. Available at: www.genome.gov/gwastudies . Accessed January 22, 2015
18 Kindmark A, Jawaid A, Harbron CG , et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008; 8 (3) 186-195
19 Maria VA, Victorino RM. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 1997; 41 (4) 534-540
20 Daly AK, Donaldson PT, Bhatnagar P , et al; DILIGEN Study; International SAE Consortium. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41 (7) 816-819
21 Baldo BA, Pham NH, Weiner J. Detection and side-chain specificity of IgE antibodies to flucloxacillin in allergic subjects. J Molecul Recogn 1995; 8: 171-177
22 Monshi MM, Faulkner L, Gibson A , et al. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 2013; 57 (2) 727-739
23 Wuillemin N, Terracciano L, Beltraminelli H , et al. T cells infiltrate the liver and kill hepatocytes in HLA-B(*)57:01-associated floxacillin-induced liver injury. Am J Pathol 2014; 184 (6) 1677-1682
24 Andrews E, Armstrong M, Tugwood J , et al. A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology 2010; 51 (5) 1656-1664
25 Singer JB, Lewitzky S, Leroy E , et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010; 42 (8) 711-714
26 Spraggs CF, Budde LR, Briley LP , et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011; 29 (6) 667-673
27 Schaid DJ, Spraggs CF, McDonnell SK , et al. Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. J Clin Oncol 2014; 32 (22) 2296-2303
28 Lucena MI, Molokhia M, Shen Y , et al; Spanish DILI Registry; EUDRAGENE; DILIN; DILIGEN; International SAEC. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011; 141 (1) 338-347
29 Stephens C, López-Nevot MA, Ruiz-Cabello F , et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS ONE 2013; 8 (7) e68111
30 Saide K, Kim S, Yuan Y , et al. Identification of susceptible HLA class II co-amoxiclav genotypes based on the analysis of drug-specific T-cells from patients with liver injury. Clin Translation Allerg 2014; 4 (Suppl. 03) O3
31 Urban TJ, Shen Y, Stolz A , et al; Drug-Induced Liver Injury Network; DILIGEN; EUDRAGENE; Spanish DILI Registry; International Serious Adverse Events Consortium. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics 2012; 22 (11) 784-795
32 Ahmadi KR, Weale ME, Xue ZY , et al. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet 2005; 37 (1) 84-89
33 Hindorff LA, Sethupathy P, Junkins HA , et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 2009; 106 (23) 9362-9367
34 Tokunaga K. Lessons from genome-wide search for disease-related genes with special reference to HLA-disease associations. Genes (Basel) 2014; 5 (1) 84-96
35 Daly AK. Pharmacogenomics of adverse drug reactions. Genome Med 2013; 5 (1) 5
36 Kaniwa N, Saito Y. Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury. J Hum Genet 2013; 58 (6) 317-326
37 Yip VLM, Alfirevic A, Pirmohamed M. Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review. Clin Rev Allergy Immunol 2015; 48 (2–3) 165-175
38 Donaldson P. Immunogenetics of autoimmune liver disease. In: Gershwin ME, Vierling J, Manns M, eds. Liver Immunology. New York, NY: Humana Press; 2007: 221-233
39 Hirata K, Takagi H, Yamamoto M , et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 2008; 8 (1) 29-33
40 Kurosaki M, Takagi H, Mori M. HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin. Dig Dis Sci 2000; 45 (6) 1103-1108
41 Pariente EA, Hamoud A, Goldfain D , et al. [Hepatitis caused by clometacin (Dupéran). Retrospective study of 30 cases. A model of autoimmune drug-induced hepatitis?]. Gastroenterol Clin Biol 1989; 13 (10) 769-774
42 Phillips E, Bartlett JA, Sanne I , et al. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr 2013; 62 (2) e55-e57
43 Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166 (7) 916-919
44 Uetrecht J. Immunoallergic drug-induced liver injury in humans. Semin Liver Dis 2009; 29 (4) 383-392
45 Aithal GP, Ramsay L, Daly AK , et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004; 39 (5) 1430-1440
46 Jenkins RE, Meng X, Elliott VL, Kitteringham NR, Pirmohamed M, Park BK. Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo. Proteomics Clin Appl 2009; 3 (6) 720-729
47 Ostrov DA, Grant BJ, Pompeu YA , et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A 2012; 109 (25) 9959-9964
48 Norcross MA, Luo S, Lu L , et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 2012; 26 (11) F21-F29
49 Illing PT, Vivian JP, Dudek NL , et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012; 486 (7404) 554-558
50 Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2012; 13 (11) 1285-1306
51 Bharadwaj M, Illing P, Theodossis A, Purcell AW, Rossjohn J, McCluskey J. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol 2012; 52: 401-431
52 Wuillemin N, Adam J, Fontana S, Krähenbühl S, Pichler WJ, Yerly D. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin. J Immunol 2013; 190 (10) 4956-4964
53 Pichler WJ. Consequences of drug binding to immune receptors: Immune stimulation following pharmacological interaction with immune receptors (T-cell receptor for antigen or human leukocyte antigen) with altered peptide-human leukocyte antigen or peptide. Dermatol Sin 2013; 31: 181-190
54 Adam J, Pichler WJ, Yerly D. Delayed drug hypersensitivity: models of T-cell stimulation. Br J Clin Pharmacol 2011; 71 (5) 701-707
55 Zanni MP, von Greyerz S, Schnyder B , et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 1998; 102 (8) 1591-1598
56 Bast BJ, Zhou LJ, Freeman GJ , et al. The HB-6, CDw75, and CD76 differentiation antigens are unique cell-surface carbohydrate determinants generated by the beta-galactoside alpha 2,6-sialyltransferase. J Cell Biol 1992; 116 (2) 423-435
57 Hennet T, Chui D, Paulson JC, Marth JD. Immune regulation by the ST6Gal sialyltransferase. Proc Natl Acad Sci U S A 1998; 95 (8) 4504-4509
58 Dalziel M, Lemaire S, Ewing J, Kobayashi L, Lau JT. Hepatic acute phase induction of murine beta-galactoside alpha 2,6 sialyltransferase (ST6Gal I) is IL-6 dependent and mediated by elevation of exon H-containing class of transcripts. Glycobiology 1999; 9 (10) 1003-1008
59 Djurovic S, Le Hellard S, Kähler AK , et al. Association of MCTP2 gene variants with schizophrenia in three independent samples of Scandinavian origin (SCOPE). Psychiatry Res 2009; 168 (3) 256-258
60 Mell B, Abdul-Majeed S, Kumarasamy S , et al. Multiple blood pressure loci with opposing blood pressure effects on rat chromosome 1 in a homologous region linked to hypertension on human chromosome 15. Hypertens Res 2015; 38 (1) 61-67
61 Zhang Y, Johansson E, Miller ML , et al. Identification of a conserved anti-apoptotic protein that modulates the mitochondrial apoptosis pathway. PLoS ONE 2011; 6 (9) e25284
62 Kaur J, Sanyal SN. Modulation of inflammatory changes in early stages of colon cancer through activation of PPARgamma by diclofenac. Eur J Cancer Prev 2010; 19 (5) 319-327
63 Korman BD, Kastner DL, Gregersen PK, Remmers EF. STAT4: genetics, mechanisms, and implications for autoimmunity. Curr Allergy Asthma Rep 2008; 8 (5) 398-403
64 Urban TJ, Goldstein DB, Watkins PB. Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?. Pharmacogenomics 2012; 13 (7) 735-738
65 Andrade RJ, Robles M, Ulzurrun E, Lucena MI. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics 2009; 10 (9) 1467-1487
66 Maher B. Personal genomes: The case of the missing heritability. Nature 2008; 456 (7218) 18-21
67 Musani SK, Shriner D, Liu N , et al. Detection of gene x gene interactions in genome-wide association studies of human population data. Hum Hered 2007; 63 (2) 67-84
68 Patel SJ, Milwid JM, King KR , et al. Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure. Nat Biotechnol 2012; 30 (2) 179-183
69 Berry C. Hazardous products: Cut animal wastage in toxicology testing. Nature 2015; 523 (7561) 410
70 Food and Drug Administration. Guidance for industry clinical pharmacogenomics: premarket evaluation in early-phase clinical studies and recommendations for labeling. Silver Spring, MD: Food and Drug Administration, Office of Communications; 2013
71 Alfirevic A, Pirmohamed M. Predictive genetic testing for drug-induced liver injury: considerations of clinical utility. Clin Pharmacol Ther 2012; 92 (3) 376-380
72 Guo Y, Shi L, Hong H, Su Z, Fuscoe J, Ning B. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Sci China Life Sci 2013; 56 (2) 119-124
73 El Sherrif Y, Potts JR, Howard MR , et al. Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations?. Liver Int 2013; 33 (8) 1266-1270
74 Aithal GP. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int 2015; 35 (7) 1801-1808
75 Daly AK. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu Rev Pharmacol Toxicol 2012; 52: 21-35
76 Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology 2014; 146 (4) 914-928
77 Heap GA, Weedon MN, Bewshea CM , et al; International Serious Adverse Events Consortium; IBD Pharmacogenetics Study Group. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet 2014; 46 (10) 1131-1134